Former Drug Abuse Cmte. Chair Asks FDA To Reconsider Need For Panel
Executive Summary
FDA should reconsider its decision to disband the Drug Abuse Advisory Committee, former chair Eric Strain, MD, Johns Hopkins University, suggested during a Peripheral & Central Nervous System Drugs Advisory Committee meeting June 6.
You may also be interested in...
Xyrem Risk Management Plan Should Limit Drug's Use To Cataplexy - Cmte.
Orphan Medical's Xyrem risk management program should limit physician use of the gamma hydroxy butyrate product to treatment of cataplexy, FDA's Peripheral & Central Nervous System Drugs Advisory Committee said at its June 6 meeting.
Orphan Xyrem Daytime Sleepiness Confirmatory Data Expected In 2002
Results from Orphan Medical's Xyrem trial examining daytime sleepiness in patients with narcolepsy are expected in the third quarter of 2002.
Orphan Xyrem Daytime Sleepiness Confirmatory Data Expected In 2002
Results from Orphan Medical's Xyrem trial examining daytime sleepiness in patients with narcolepsy are expected in the third quarter of 2002.